Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.51 |
| ▸ | MEN1 | O00255 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7570783 | 0.89 | KMT2A (0.58) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7564313 | 0.88 | KMT2A (0.46) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7563947 | 0.83 | KMT2A (0.47) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7564327 | 0.82 | QRFPR (0.46) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7564256 | 0.81 | KMT2A (0.62) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7973635 | 0.81 | KMT2A (0.45) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7562379 | 0.80 | KMT2A (0.44) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7971573 | 0.79 | KMT2A (0.44) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7570363 | 0.78 | KMT2A (0.43) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL7565732 | 0.78 | KMT2A (0.43) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2001046170-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046171-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | OPRM1, HIF1AN, MAOB | KMT2A 1679/4885MEN1 3127/4885SMN1; SMN2 610/4885 |
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | NOS1, NOS2, NOS3 | KMT2A 3787/4885MEN1 2000/4885SMN1; SMN2 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.